Global Biosimilar 麻豆原创 Research Report 2024

Publication ID:

PB502246494

Publication Date:

March 4, 2024

Pages:

107

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.
In this report is a biologic defined as proteins, peptides, hormones or antibody鈥檚 drugs production by bio-engineered technology, but does not include a vaccine.
The global Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
China鈥檚 core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.
In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer锛寃ith a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar.
Report Scope
The Biosimilar market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Amgen
Biogen
Novartis
Samsung Bioepis
Viatris
Fresenius Kabi
Celltrion
Cadila Healthcare
Torrent Pharmaceuticals
Boehringer Ingelheim
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Biosimilar 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Biosimilar 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Immunological Diseases
1.3.4 Diabetes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar 麻豆原创 Perspective (2019-2030)
2.2 Biosimilar Growth Trends by Region
2.2.1 Global Biosimilar 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilar Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Biosimilar Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Biosimilar 麻豆原创 Dynamics
2.3.1 Biosimilar Industry Trends
2.3.2 Biosimilar 麻豆原创 Drivers
2.3.3 Biosimilar 麻豆原创 Challenges
2.3.4 Biosimilar 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Players by Revenue
3.1.1 Global Top Biosimilar Players by Revenue (2019-2024)
3.1.2 Global Biosimilar Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Biosimilar 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar Revenue
3.4 Global Biosimilar 麻豆原创 Concentration Ratio
3.4.1 Global Biosimilar 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Revenue in 2023
3.5 Biosimilar Key Players Head office and Area Served
3.6 Key Players Biosimilar Product Solution and Service
3.7 Date of Enter into Biosimilar 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar Breakdown Data by Type
4.1 Global Biosimilar Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Biosimilar Forecasted 麻豆原创 Size by Type (2025-2030)
5 Biosimilar Breakdown Data by Application
5.1 Global Biosimilar Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Biosimilar Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Biosimilar 麻豆原创 Size (2019-2030)
6.2 North America Biosimilar 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilar 麻豆原创 Size by Country (2019-2024)
6.4 North America Biosimilar 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar 麻豆原创 Size (2019-2030)
7.2 Europe Biosimilar 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilar 麻豆原创 Size by Country (2019-2024)
7.4 Europe Biosimilar 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Biosimilar 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilar 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilar 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar 麻豆原创 Size (2019-2030)
9.2 Latin America Biosimilar 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilar 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Biosimilar 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Biosimilar 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilar 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilar 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Biosimilar Introduction
11.1.4 Pfizer Revenue in Biosimilar Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Biosimilar Introduction
11.2.4 Amgen Revenue in Biosimilar Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen Biosimilar Introduction
11.3.4 Biogen Revenue in Biosimilar Business (2019-2024)
11.3.5 Biogen Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Biosimilar Introduction
11.4.4 Novartis Revenue in Biosimilar Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Samsung Bioepis
11.5.1 Samsung Bioepis Company Detail
11.5.2 Samsung Bioepis Business Overview
11.5.3 Samsung Bioepis Biosimilar Introduction
11.5.4 Samsung Bioepis Revenue in Biosimilar Business (2019-2024)
11.5.5 Samsung Bioepis Recent Development
11.6 Viatris
11.6.1 Viatris Company Detail
11.6.2 Viatris Business Overview
11.6.3 Viatris Biosimilar Introduction
11.6.4 Viatris Revenue in Biosimilar Business (2019-2024)
11.6.5 Viatris Recent Development
11.7 Fresenius Kabi
11.7.1 Fresenius Kabi Company Detail
11.7.2 Fresenius Kabi Business Overview
11.7.3 Fresenius Kabi Biosimilar Introduction
11.7.4 Fresenius Kabi Revenue in Biosimilar Business (2019-2024)
11.7.5 Fresenius Kabi Recent Development
11.8 Celltrion
11.8.1 Celltrion Company Detail
11.8.2 Celltrion Business Overview
11.8.3 Celltrion Biosimilar Introduction
11.8.4 Celltrion Revenue in Biosimilar Business (2019-2024)
11.8.5 Celltrion Recent Development
11.9 Cadila Healthcare
11.9.1 Cadila Healthcare Company Detail
11.9.2 Cadila Healthcare Business Overview
11.9.3 Cadila Healthcare Biosimilar Introduction
11.9.4 Cadila Healthcare Revenue in Biosimilar Business (2019-2024)
11.9.5 Cadila Healthcare Recent Development
11.10 Torrent Pharmaceuticals
11.10.1 Torrent Pharmaceuticals Company Detail
11.10.2 Torrent Pharmaceuticals Business Overview
11.10.3 Torrent Pharmaceuticals Biosimilar Introduction
11.10.4 Torrent Pharmaceuticals Revenue in Biosimilar Business (2019-2024)
11.10.5 Torrent Pharmaceuticals Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Detail
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Biosimilar Introduction
11.11.4 Boehringer Ingelheim Revenue in Biosimilar Business (2019-2024)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Company Detail
11.12.2 Qilu Pharmaceutical Business Overview
11.12.3 Qilu Pharmaceutical Biosimilar Introduction
11.12.4 Qilu Pharmaceutical Revenue in Biosimilar Business (2019-2024)
11.12.5 Qilu Pharmaceutical Recent Development
11.13 Bio-Thera
11.13.1 Bio-Thera Company Detail
11.13.2 Bio-Thera Business Overview
11.13.3 Bio-Thera Biosimilar Introduction
11.13.4 Bio-Thera Revenue in Biosimilar Business (2019-2024)
11.13.5 Bio-Thera Recent Development
11.14 Zhejiang Hisun
11.14.1 Zhejiang Hisun Company Detail
11.14.2 Zhejiang Hisun Business Overview
11.14.3 Zhejiang Hisun Biosimilar Introduction
11.14.4 Zhejiang Hisun Revenue in Biosimilar Business (2019-2024)
11.14.5 Zhejiang Hisun Recent Development
11.15 Shanghai Henlius
11.15.1 Shanghai Henlius Company Detail
11.15.2 Shanghai Henlius Business Overview
11.15.3 Shanghai Henlius Biosimilar Introduction
11.15.4 Shanghai Henlius Revenue in Biosimilar Business (2019-2024)
11.15.5 Shanghai Henlius Recent Development
11.16 Innovent Biologics
11.16.1 Innovent Biologics Company Detail
11.16.2 Innovent Biologics Business Overview
11.16.3 Innovent Biologics Biosimilar Introduction
11.16.4 Innovent Biologics Revenue in Biosimilar Business (2019-2024)
11.16.5 Innovent Biologics Recent Development
11.17 Jiangsu Hengrui
11.17.1 Jiangsu Hengrui Company Detail
11.17.2 Jiangsu Hengrui Business Overview
11.17.3 Jiangsu Hengrui Biosimilar Introduction
11.17.4 Jiangsu Hengrui Revenue in Biosimilar Business (2019-2024)
11.17.5 Jiangsu Hengrui Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Detail
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Biosimilar Introduction
11.18.4 Gan&Lee Revenue in Biosimilar Business (2019-2024)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Detail
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Biosimilar Introduction
11.19.4 Tonghua Dongbao Revenue in Biosimilar Business (2019-2024)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Detail
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Biosimilar Introduction
11.20.4 United Laboratory Revenue in Biosimilar Business (2019-2024)
11.20.5 United Laboratory Recent Development
11.21 3SBIO
11.21.1 3SBIO Company Detail
11.21.2 3SBIO Business Overview
11.21.3 3SBIO Biosimilar Introduction
11.21.4 3SBIO Revenue in Biosimilar Business (2019-2024)
11.21.5 3SBIO Recent Development
11.22 Luye Pharma
11.22.1 Luye Pharma Company Detail
11.22.2 Luye Pharma Business Overview
11.22.3 Luye Pharma Biosimilar Introduction
11.22.4 Luye Pharma Revenue in Biosimilar Business (2019-2024)
11.22.5 Luye Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Amgen
Biogen
Novartis
Samsung Bioepis
Viatris
Fresenius Kabi
Celltrion
Cadila Healthcare
Torrent Pharmaceuticals
Boehringer Ingelheim
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.